True Leaf Medicine International, which is building a medical marijuana plant in Lumby, is forming a medical Advisory Board with Vernon Naturopath Dr. Chris Spooner as the Chief Scientific Officer.
He’ll head a team of leading B.C. medical practitioners committed to advancing integrative healthcare with cannabis.
The board is to oversee the research and development of a highly-effective medicinal cannabis product line to address, among others, neurological, musculoskeletal, gynaecological, and gastrointestinal conditions.
Dr Spooner has more than 20 years of experience in naturopathic medicine.
He is also a board member of the College of Naturopathic Physicians of British Columbia and adjunct professor for several naturopathic colleges.
“We want to help True Leaf build trust in the medical community. True Leaf is unique because it is committed to the whole plant medicine. Fifty percent of the medicine comes from components other than CBD or THC, and we want to take the lead on research and development of the potential of the whole plant. True Leaf has brought us in right at the beginning of the project development phase so we are set to collaborate on selecting effective strains and begin pilot trials on whole plant medicines and extractions.”
Dr. Spooner will be joined by Dr. Caroline MacCallum and Dr. Zeid Mohamedali, who are considered two of the most progressive medical doctors advising the cannabis industry today.
Dr. MacCallum is an internal medicine specialist with a background in pharmacy and expertise in complex pain and cannabinoid medicine and is a clinical instructor in the Department of Medicine at the University of British Columbia.
She has extensive clinical training in the field of medical cannabis and has developed cannabinoid treatment plans for more than 2,000 patients and has presented internationally on the topic.
“True Leaf stands out because they started with hemp-seed based supplements for pets,” says Dr. MacCallum. “They are now also focused on cannabis genetics for several niche patient populations where therapeutic options are limited or ineffective. I have seen first-hand how powerful cannabis can be in the management of complex diseases and polypharmacy reduction. What meaningful research can we do in the cannabis space to fill the knowledge gaps? What is the best combination of cannabinoids for each patient? These are the issues we will be tackling.”
Dr. Mohamedali is an urologist and researcher with a special interest in uro-oncology and pelvic floor dysfunction.
Dr. Mohamedali has more than 20 years of experience in clinical research and surgical practice.
His medical cannabis practice is focused on treatments for pain related to chronic pelvic pain, musculoskeletal trauma, and cancer.
He also serves as the Chief Executive Officer of the Greenleaf Medical Clinics, one of Canada’s top telehealth cannabis organizations.
“These are exciting times in healthcare,” said Dr. Mohamedali. “Companies like True Leaf are reshaping how we view many medical conditions. Traditional treatment algorithms are being modified to accommodate the inclusion of cannabis. The True Leaf MAB will be using unique plant chemovars, nanotechnology, genetics, and much more to provide cutting edge treatments. We hope our efforts will have a dramatic impact on many patients and their loved ones.”
“Today’s announcement is a significant milestone in our mission to be Canada’s leading purpose-driven cannabis company,” said Darcy Bomford, Founder and Chief Executive Officer of True Leaf. “Our MAB has the expertise to help us research and develop world-class medicinal cannabis products that fill the gaps that exist in medical treatment today. These doctors have extensive success treating patients with cannabis who have found their pharmaceutical treatments ineffective or intolerable. They have taken a progressive approach to treating their patients, and because of that, have helped people live happier, healthier lives.”
True Leaf is currently in the final stages of Health Canada’s Access to Cannabis for Medical Purposes Regulations process.